سعر فلاجيلات فورت معلق 200 مجم/5 مل 100 مل 2026

Flagellat Forte oral suspension: benzoyl metronidazole 320 mg/5 ml (equivalent to metronidazole 200 mg/5 ml), 100 ml amber glass bottle with dosing cup, Medical Union Pharmaceuticals (MUP), Egypt.

• Prevention and treatment of anaerobic bacterial infections (e.g. postoperative, septicaemia, brain abscess, pneumonia, osteomyelitis, peritonitis, pelvic and puerperal infections, wound infections); urogenital trichomoniasis; intestinal and hepatic amoebiasis; giardiasis; acute ulcerative gingivitis. In patients over 10 years: bacterial vaginosis, dental infections and leg/pressure ulcers. In children: eradication of Helicobacter pylori. Neonatal use is limited to newborns with a gestational age over 40 weeks for anaerobic infections.Population: Adults, children and newborns (gestational age over 40 weeks) as labelledEgyptian Drug Authority (EDA) e-services

• Unpleasant taste, oral mucositis, furred tongue, nausea, vomiting, epigastric pain, diarrhoea, anorexia; urticaria, angioedema, fever and rare anaphylaxis; very rarely drowsiness, dizziness, headache, convulsions, ataxia, encephalopathy/subacute cerebellar syndrome, psychotic disorders, visual disturbances, agranulocytosis/neutropenia/thrombocytopenia, hepatitis/jaundice/pancreatitis, rashes, myalgia/arthralgia and darkening of urine; peripheral neuropathy with intensive/prolonged therapy; moderate transient leucopenia; SJS/TEN reported (frequency not known).Egyptian label · Egyptian Drug Authority (EDA) e-services

• Known hypersensitivity to metronidazole, nitroimidazoles and/or hydroxybenzoates (parabens) or any of the excipients.Egyptian label · Egyptian Drug Authority (EDA) e-services

• Regular clinical and laboratory monitoring (including leucocyte count) if treatment lasts more than 10 days; watch for peripheral or central neuropathy (paraesthesia, ataxia, dizziness, convulsions); caution in active or chronic severe peripheral and central nervous system disease; severe hepatotoxicity/acute liver failure reported in Cockayne syndrome (liver function tests before, during and after therapy); urine may darken; prolonged treatment beyond the usual duration should be carefully considered; contains sucrose 1.5 g per 5 ml (not for hereditary fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency; consider in diabetes) and methyl/propyl parabens (possible delayed allergic reactions).Egyptian label · Egyptian Drug Authority (EDA) e-services

• AlcoholDisulfiram-like reaction; avoid alcohol during treatment and for at least 48 hours afterwards.Egyptian Drug Authority (EDA) e-services
• DisulfiramPsychotic reactions reported with concomitant use.Egyptian Drug Authority (EDA) e-services
• Warfarin / oral anticoagulantsPotentiated anticoagulant effect and bleeding risk; monitor prothrombin time and adjust.Egyptian Drug Authority (EDA) e-services

• Inadequate evidence of safety in pregnancy: should not be given during pregnancy unless the physician considers it essential, and then short high-dose regimens are not recommended.Egyptian label · Egyptian Drug Authority (EDA) e-services
• A significant amount passes into breast milk (may give it a bitter taste); not to be given during lactation unless essential, and breastfeeding should be avoided after a large dose.Egyptian label · Egyptian Drug Authority (EDA) e-services

• Metronidazole (as benzoyl metronidazole): The nitro group acts as an electron acceptor and is reduced to a chemically reactive form that causes biochemical lesions, mainly in DNA (loss of helical structure and inhibition of synthesis), leading to cell death; selective for anaerobes and hypoxic cells (Egyptian leaflet).

Store at a temperature not exceeding 30 °C, protected from light; shelf life 3 years; shake well before use.